San Diego-based Regulus Therapeutics, the developer of microRNA therapies, said today it has formed a research collaboration with UC San Diego. The partners will seek to develop microRNA therapies that work to block new blood vessel formation (anti-angiogenesis), as a way to treat various diesases, Regulus said in a statement. Financial terms of the deal aren’t being disclosed, although the work is being supported by a UC Discovery Grant, Regulus said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
